Do hEDS and HSD Get Worse Over Time? Long-Term Outlook
At a Glance
hEDS and HSD do not inevitably worsen in a steady, predictable way. Symptoms fluctuate with age, activity, stress, illness, and hormones; individualized rehabilitation and pacing can support function, and there is no strong evidence that either condition shortens life expectancy.
In this answer
4 sections
Does hypermobile Ehlers-Danlos Syndrome (hEDS) or Hypermobility Spectrum Disorder (HSD) inevitably get worse over time? Observational evidence and clinical consensus suggest that these conditions do not follow a uniformly predictable or inevitable downward trajectory [1]. While hEDS and HSD can cause substantial, lifelong challenges with pain, fatigue, and joint instability, a variable course is common [1]. Treatment focuses on supporting function and quality of life, and many people report subjective improvement in symptoms with individualized rehabilitation and pacing [2].
It is important to note that hEDS is a clinical diagnosis, while HSD is a broader umbrella term for symptomatic joint hypermobility. Research often groups them together, but your individual course may vary depending on your specific symptoms and overlap with other conditions.
The Variable Course of Hypermobility
Rather than a steady, inevitable decline, the natural history of hEDS and HSD is often characterized by fluctuations. You may experience “flares,” where symptoms temporarily worsen due to an acute injury, illness, stress, or hormonal changes [1].
As you age, the way hypermobility affects your body may change. While joint flexibility often naturally decreases (stiffens) as people get older, this does not mean the underlying connective tissue condition has resolved [1]. Older adults with hEDS and HSD frequently continue to experience pain, fatigue, orthostatic symptoms (like dizziness upon standing), and gastrointestinal issues [3][4]. However, long-term observational studies suggest that while people with hEDS or HSD may have lower baseline muscle strength, this strength does not necessarily decline at a faster rate over time compared to people without the condition [5].
What Can Change Over Time?
- Joint Range of Motion: May decrease naturally with age, leading to a feeling of stiffness rather than looseness.
- Pain and Instability: Often fluctuate with activity levels, stress, or hormonal shifts (such as menopause).
- Muscle Conditioning: Can decline if fear of injury leads to prolonged inactivity, worsening joint instability.
Supporting Function Over Time
Because the course is variable, treatment focuses on supporting your physical function and minimizing symptom flares. Observational studies suggest that therapeutic exercise and motor-function training can be beneficial [6][7]. In one real-world study of adults with hEDS/HSD, 54% reported feeling subjectively better after roughly 20 months of coordinated physical therapy [2]. However, no single treatment guarantees improvement, and needing mobility aids, accommodations, or pain management is a valid part of taking care of yourself, not a sign of failure.
To support your joints and energy levels:
- Condition-Specific Rehabilitation: Working with a physical therapist can help you build strength, endurance, proprioception (body awareness), and motor control to stabilize joints [6]. Therapists should help you avoid rapid progression, uncontrolled heavy loading, and repeated end-range stretching, which can cause treatment-related injuries [8][9].
- Pacing and Rest: Balancing daily activities helps avoid the “push-crash” cycle [10]. If you experience post-exertional malaise (a severe worsening of symptoms after physical or mental effort) or significant orthostatic intolerance (dizziness/racing heart when upright), your activity plan must be carefully adapted to include necessary rest [8][11].
Life Expectancy: hEDS vs. Vascular EDS
It is common to encounter alarming statistics about EDS online, but it is vital to distinguish between hEDS/HSD and Vascular Ehlers-Danlos Syndrome (vEDS).
vEDS is a distinct, rare genetic condition (typically involving the COL3A1 gene) characterized by extreme fragility of blood vessels and hollow organs [12]. People with vEDS face a high risk of life-threatening complications, such as early spontaneous arterial or digestive ruptures. Historical cohorts placed median life expectancy around 40 to 50 years, though this is a population estimate and not an individual prediction [13][14].
In contrast, there is no strong evidence that hEDS or HSD alone shortens life expectancy [13][15]. While some people with hEDS or HSD may have mild dilation of the aortic root (the start of the main artery from the heart), this is generally mild [15]. Not everyone requires lifelong cardiac imaging. A clinician may recommend a baseline echocardiogram based on your physical exam, personal or family history, or symptoms; whether you need repeat imaging depends entirely on those individualized findings [15][16].
When Worsening Symptoms Need a Fresh Look
Because hEDS and HSD do not typically cause rapid, irreversible deterioration, you should never assume a sudden, severe worsening of health is just part of the condition.
Other factors that require specific clinical evaluation include:
- Autonomic and Immunologic Conditions: Postural Orthostatic Tachycardia Syndrome (POTS) and conditions like Mast Cell Activation Syndrome (MCAS) are sometimes seen in people with hypermobility [17]. However, ordinary dizziness or fatigue does not automatically mean you have POTS, and MCAS requires specific diagnostic testing rather than just symptom overlap [17].
- Gastrointestinal Issues: Common causes of severe nausea or abdominal pain should be evaluated first. While rare motility issues or vascular compression syndromes can occur, a symptom-based evaluation is required to rule out standard gastrointestinal diseases [17][18].
- Alternative Diagnoses: If you develop atypical features—such as unexpected inflammatory signs, unusual skin fragility, or new vascular features—your doctor may need to reassess your diagnosis. Some people initially diagnosed with hEDS are later found to have other heritable connective tissue disorders that require different management [19].
🚨 When to Seek Emergency Care
Most symptom flares are not dangerous, but certain symptoms require immediate emergency assessment rather than a routine clinic visit [12][20]:
- Sudden, severe chest, abdominal, or back pain
- Fainting or collapsing
- New severe weakness, numbness, or difficulty speaking
- Severe shortness of breath
- Significant or unexplained bleeding
- An acutely injured joint with loss of circulation, loss of sensation, or an inability to bear weight
Common questions in this guide
Do hEDS and HSD inevitably get worse as I age?
What does aging typically do to hEDS and HSD symptoms?
Can physical therapy help my long-term outlook with hEDS or HSD?
Does hEDS or HSD shorten life expectancy?
When should new or worsening symptoms be checked urgently?
Will I need an echocardiogram if I have hEDS or HSD?
Related questions
Show more
Get notified when new evidence is published on hypermobility syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (20)
- 1
Clinical trajectory of hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders in older adults.
Anderson LK, Lane KR
Journal of the American Association of Nurse Practitioners 2023; (35(10)):605-612 doi:10.1097/JXX.0000000000000900.
PMID: 37261967 - 2
Are patients with hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorder so different?
Aubry-Rozier B, Schwitzguebel A, Valerio F, et al.
Rheumatology international 2021; (41(10)):1785-1794 doi:10.1007/s00296-021-04968-3.
PMID: 34398260 - 3
Health-Related Quality of Life in Midlife and Older Women With Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders.
Anderson LK
Nursing for women's health 2026; (30(2)):85-92 doi:10.1016/j.nwh.2025.09.006.
PMID: 41587761 - 4
Hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders in older women: A feasibility study.
Anderson LK, Lane KR
Musculoskeletal care 2023; (21(3)):741-748 doi:10.1002/msc.1747.
PMID: 36864687 - 5
Does Muscle Strength Change Over Time in Patients With Hypermobile Ehlers-Danlos Syndrome/Hypermobility Spectrum Disorder? An Eight-Year Follow-Up Study.
Coussens M, Calders P, Lapauw B, et al.
Arthritis care & research 2021; (73(7)):1041-1048 doi:10.1002/acr.24220.
PMID: 32293111 - 6
Physical therapy interventions in generalized hypermobility spectrum disorder and hypermobile Ehlers-Danlos syndrome: a scoping review.
Garreth Brittain M, Flanagan S, Foreman L, Teran-Wodzinski P
Disability and rehabilitation 2024; (46(10)):1936-1953 doi:10.1080/09638288.2023.2216028.
PMID: 37231592 - 7
Home-based exercise therapy for treating shoulder instability in patients with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders. A randomized trial.
Spanhove V, De Wandele I, Malfait F, et al.
Disability and rehabilitation 2023; (45(11)):1811-1821 doi:10.1080/09638288.2022.2076932.
PMID: 35609204 - 8
Exercise beliefs and behaviours of individuals with Joint Hypermobility syndrome/Ehlers-Danlos syndrome - hypermobility type.
Simmonds JV, Herbland A, Hakim A, et al.
Disability and rehabilitation 2019; (41(4)):445-455 doi:10.1080/09638288.2017.1398278.
PMID: 29125009 - 9
Managing Patients With Hypermobility Disorders: They've Seen You, but Have You Seen Them?
Mintken PE, Dommerholt J, Francomano CA
The Journal of orthopaedic and sports physical therapy 2026; (56(8)):478-481 doi:10.2519/jospt.2026.13979.
PMID: 42538787 - 10
Developing a self-management intervention to manage hypermobility spectrum disorders (HSD) and hypermobile Ehlers-Danlos syndrome (hEDS): an analysis informed by behaviour change theory.
Bennett SE, Walsh N, Moss T, Palmer S
Disability and rehabilitation 2022; (44(18)):5231-5240 doi:10.1080/09638288.2021.1933618.
PMID: 34101520 - 11
Dysautonomia in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders is associated with exercise intolerance and cardiac atrophy.
Ruiz Maya T, Fettig V, Mehta L, et al.
American journal of medical genetics. Part A 2021; (185(12)):3754-3761 doi:10.1002/ajmg.a.62446.
PMID: 34331416 - 12
Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome.
Byers PH, Belmont J, Black J, et al.
American journal of medical genetics. Part C, Seminars in medical genetics 2017; (175(1)):40-47 doi:10.1002/ajmg.c.31553.
PMID: 28306228 - 13
Ruptured ulnar artery aneurysm in vascular Ehlers-Danlos syndrome.
Howard R, Osborne N
Journal of vascular surgery cases and innovative techniques 2020; (6(1)):71-74 doi:10.1016/j.jvscit.2019.11.013.
PMID: 32072093 - 14
The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers-Danlos syndrome.
Frank M, Albuisson J, Ranque B, et al.
European journal of human genetics : EJHG 2015; (23(12)):1657-64 doi:10.1038/ejhg.2015.32.
PMID: 25758994 - 15
Cardiovascular manifestations of hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders.
Rashed ER, Ruiz Maya T, Black J, et al.
Vascular medicine (London, England) 2022; (27(3)):283-289 doi:10.1177/1358863X211067566.
PMID: 35000503 - 16
Longitudinal echocardiography in pediatric patients with hypermobile Ehlers-Danlos syndrome.
Lahey H, Shin H, Myers K, McBride KL
American journal of medical genetics. Part A 2024; (194(12)):e63844 doi:10.1002/ajmg.a.63844.
PMID: 39148461 - 17
AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.
Aziz Q, Harris LA, Goodman BP, et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2025; (23(8)):1291-1302 doi:10.1016/j.cgh.2025.02.015.
PMID: 40387691 - 18
Mast cell activation and nutritional disorders in patients with hypermobility.
Penny HA, Aziz I, Lam C
Current opinion in gastroenterology 2024; (40(3)):225-232 doi:10.1097/MOG.0000000000001008.
PMID: 38393310 - 19
Hypermobile Ehlers-Danlos Syndrome: Diagnostic Challenges and the Role of Genetic Testing.
Forghani I, See J, McGonigle WC
Genes 2025; (16(5)) doi:10.3390/genes16050530.
PMID: 40428350 - 20
Spontaneous pneumothorax and hemothorax frequently precede the arterial and intestinal complications of vascular Ehlers-Danlos syndrome.
Shalhub S, Neptune E, Sanchez DE, et al.
American journal of medical genetics. Part A 2019; (179(5)):797-802 doi:10.1002/ajmg.a.61094.
PMID: 30793832
This page explains the variable long-term course of hEDS and HSD for informational purposes only and does not replace medical advice. Discuss symptom changes, testing, and emergency concerns with your healthcare professional.